Active substanceCyproteroneCyproterone
Similar drugsTo uncover
  • Androkur®
    pills inwards 
    Bayer Pharma AG     Germany
  • Androkur®
    pills inwards 
    Bayer Pharma AG     Germany
  • Androkur®
    pills inwards 
    Bayer Pharma AG     Germany
  • Androkur® Depot
    solution w / m 
    Bayer Pharma AG     Germany
  • Cyproterone-Teva
    pills inwards 
  • Dosage form: & nbsppills
    Composition:

    One tablet contains:

    Active substance:

    cyproterone acetate, micro 20 - 100.0 mg

    Excipients:

    lactose monohydrate 193.0 mg, corn starch 100.0 mg, povidone 25,000 4.0 mg, magnesium stearate 3.0 mg.

    Description:

    The capsule-shaped, white to light-yellow tablets, with a risk on one side, on both sides, the risks are "LA". On the other side of the tablet a hexagon is squeezed out.

    Pharmacotherapeutic group:Antiandrogen
    ATX: & nbsp

    G.03.H.A.01   Cyproterone

    Pharmacodynamics:

    Androkur® is an anti-androgenic hormone drug.

    Cyproterone, by a competitive mechanism, inhibits the action of androgens on their target organs, for example, protects the prostate gland from the action of androgens of the sex glands and / or the adrenal cortex. Cyproterone has a central antigonadotropic effect, leading to a decrease in the synthesis of testosterone in the testicles, and its content in the serum.As a result, the androgenic stimulation of prostate tissue is suppressed. In men with the use of Androkur®, depression of sexual desire, potency and function of the testicles is observed. These effects are completely reversible and pass after discontinuation of treatment. The antigonadotropic effect of cyproterone also appears in combination with gonadotropin-releasing hormone agonists (GnRH). The temporary increase in serum testosterone concentration, observed at the initial stage of GnRH agonist therapy, decreases with the intake of cyproterone. Sometimes, when taking high doses of cyproterone, there was an increase in the concentration of prolactin.

    Systemic Toxicity. According to standard preclinical toxicity studies with repeated long-term administration, there is no specific risk to humans.

    Pharmacokinetics:

    Absorption. Cyproterone completely absorbed after ingestion. Absolute bioavailability of cyproterone is about 88%.

    Distribution. The maximum concentration of cyproterone (Cmax) in the blood serum after taking a dose of 100 mg reaches 239.2 ± 114.2 ng / ml on average after 2.8 ± 1.1 hours.Reduction of serum ciproterone concentration is biphasic and occurs within 24-120 h with a final half-life (T1 / 2) of 42.8 ± 9.7 hours. The total clearance of ciproterone from serum is 3.8 ± 2.2 ml / min / kg. Cyproterone almost completely binds to plasma albumins. About 3.5-4% of cyproterone remains unbound. Since the association with proteins is non-specific, a change in the content of globulin binding the sex hormones does not affect the pharmacokinetics of cyproterone. Due to the long period of elimination in the final phase of elimination from plasma, as well as daily intake, it is probable that ciproteron cumulation in serum is 3 times greater when repeated doses are used per one treatment cycle.

    Metabolism / biotransformation. Cyproterone is metabolized by hydroxylation and conjugation. The main metabolite in the blood plasma is the 15β-hydroxy derivative. The first phase of metabolism is mainly catalyzed by the cytochrome P450 isoenzyme CYP3A4.

    Excretion. It is exposed to biotransformation in the liver, it is excreted mainly as metabolites with bile and kidneys (half-life of 1.9 days) in a ratio of 3: 7, part is excreted unchanged with bile. Metabolism in the blood plasma occurs at the same rate (half-life of 1.7 days).

    Indications:

    Common inoperable or metastatic prostate cancer when it is necessary to suppress the action of testosterone:

    • antiandrogen therapy for inoperable prostate cancer;
    • reduction in the severity of hyperandrogenism observed at the beginning of therapy with gonadotropin-releasing hormone agonists (GnRH);
    • relief of tides in patients with prostate cancer receiving therapy with GnRH agonists, or in patients undergoing orchiectomy.
    Contraindications:
    • Hypersensitivity to cyproterone or other components of the drug.
    • Diseases of the liver (including Dubin-Johnson syndrome, Rotor syndrome), a history of liver tumors or at present (with the exception of metastases of prostate cancer in the liver).
    • Cachexia (with the exception of cachexia in prostate cancer).
    • Severe chronic depression.
    • Thrombosis and thromboembolism are now.
    • The presence of a meningioma at the present time or in an anamnesis.
    • Children and adolescents under 18 years.
    Carefully:

    In the presence of patients with inoperable prostate cancer, thrombosis and thromboembolism in history, severe diabetes mellitus with angiopathy,sickle-cell anemia Androkur® is assigned only after evaluating the individual benefit-risk ratio in each case.

    Patients with rare hereditary diseases of milk sugar intolerance, lactase deficiency, glucose malabsorption syndrome and galactose should apply this medication with caution.

    Dosing and Administration:

    Tablets should be taken daily inside after eating, squeezed with a small amount of liquid. If signs of disease progression appear, the drug should be discontinued.

    The maximum daily dose of Androkur® is 300 mg.

    Antiandrogen therapy for inoperable prostate cancer

    For 200-300 mg per day (1 tablet 2-3 times a day). If the condition improves or remission is achieved, treatment should not be discontinued or the dose reduced.

    Reduction of the severity of hyperandrogenism observed at the beginning of therapy with gonadotropin-releasing hormone agonists (GnRH);

    200 mg per day (1 tablet 2 times a day) as monotherapy for 5-7 days, then for 3-4 weeks at the same dose in combination with GnRH analogues at the dose recommended by the manufacturer.

    Coping of "hot flashes" in patients with prostate cancer receiving therapy with GnRH agonists, or in patients undergoing orchiectomy.

    For 50-150 mg per day (½-1½ tablets per day) if necessary, followed by a dose increase of up to 300 mg per day (1 tablet 3 times a day).

    Application in certain categories of patients:

    Children and adolescence

    Androkur® is not recommended for use in children and adolescents under 18 due to insufficient information on efficacy and safety in this category of patients.

    Elderly age

    There is no data on the need to change the dose of the drug in elderly patients.

    Liver failure

    The use of the drug Androkur® is contraindicated in patients with liver disease (until the liver is normalized).

    Renal insufficiency

    There is no data on the need to change the dose in this category of patients.

    Side effects:

    The most frequently observed side effects: decreased libido, impotence and reversible suppression of spermatogenesis.

    The most serious side effects are hepatotoxicity, benign and malignant liver tumors, which can lead to intra-abdominal bleeding and the development of thromboembolic processes.

    The adverse events reported in the use of Androkur® are listed below. The frequency is defined as: very often (≥1 / 10), often (from ≥1 / 100 to <1/10), infrequently (from ≥ 1/1000 to <1/100), rarely (from ≥ 1/10000 to < 1/1000), very rarely (<1/10000). For undesirable effects, revealed only in the process of postmarketing observations and for which it is not possible to estimate the frequency, "frequency is unknown" is indicated.

    From the hematopoietic system:

    frequency unknown - anemia *).

    From the immune system:

    rarely - hypersensitivity reactions.

    Disorders of the psyche:

    often - depression, depressed mood, anxiety (temporarily).

    From the side of the vessels:

    frequency unknown - thrombosis and thromboembolism *) **).

    On the part of the respiratory system:

    often - shortness of breath *).

    From the gastrointestinal tract:

    frequency unknown - intra-abdominal hemorrhage *).

    From the liver and biliary tract:

    often - jaundice, hepatitis, liver failure *).

    From the skin and subcutaneous tissues:

    infrequent - rash.

    From the musculoskeletal system:

    frequency is unknown - osteoporosis.

    From the genitals and mammary glands:

    very often - reversible suppression of spermatogenesis, decreased libido, erectile dysfunction; often - gynecomastia.

    Other:

    often - increase or decrease in body weight, increased fatigue, "hot flashes", increased sweating; very rarely - the development of benign or malignant liver tumors *); frequency unknown - development of meningioma *) §).

    Undesirable phenomena for which you can find more detailed information in the section "Special instructions" are marked with an asterisk *). Undesirable phenomena for which a causal relationship with the administration of Androcur® has not been proven is indicated by asterisks **. §) - refer to the section "Contraindications".

    Against the background of treatment with the drug Androkur®, sexual desire and potency decrease, in addition, the function of the sexual glands is suppressed. These changes are reversible and pass after the withdrawal of therapy.

    Within a few weeks, as a result of antiandrogenic and antigonadotropic actions of the Androkur® preparation, spermatogenesis is suppressed, which is gradually restored several months after the abolition of therapy.

    In men, taking Androcur® can lead to the development of gynecomastia (which is sometimes accompanied by increased tactile sensitivity and soreness of the nipples), which usually occurs after drug withdrawal or dose reduction.

    As with the use of other anti-androgenic drugs, the long-term androgen deficiency caused by Androkur® can lead to the development of osteoporosis. The development of meningiomas has been reported due to the long-term (for several years) administration of Androkur® in a dose of 25 mg or more.

    Overdose:

    Studies of acute toxicity after a single application of the drug showed that cyproterone can be considered practically non-toxic substance. The risk of acute intoxication after a single random dose, several times higher than the recommended therapeutic dose, is unlikely. There is no specific antidote. If necessary, symptomatic therapy is recommended.

    Interaction:

    Patients with diabetes need to be closely monitored, as the need for oral hypoglycemic agents or insulin may change.

    Because the cyproterone is metabolized by the CYP3A4 isoenzyme, it is expected that its combined use with ketoconazole, itraconazole, clotrimazole, ritonavir and other potent inhibitors of the CYP3A4 isoenzyme will suppress the metabolism of cyproterone.Inductors of the isoenzyme CYP3A4, such as rifampicin, phenytoin and herbal preparations based on St. John's wort, can reduce the concentration of cyproterone.

    In vitro studies have shown that at high therapeutic doses of cyproterone (100 mg 3 times daily) it is possible to inhibit the isoenzymes of the cytochrome P450 system, such as CYP2C8, 2C9, 2C19, 3A4 and 2D6. However, in in vivo studies, interaction with CYP2C8 substrates (for example, pioglitazone, rosiglitazone) has not been studied or recorded.

    When the high doses of cyproterone are combined with HMG-CoA reductase inhibitors (statins), which are also metabolized predominantly by the CYP3A4 isoenzyme, the risk of myopathy and rhabdomyolysis associated with taking statins may increase.

    Special instructions:

    There are reports of a direct dose-dependent toxic effect of Androkur® on the liver (development of jaundice, hepatitis and liver failure). In addition, when the drug was used at a dose of 100 mg or higher, fatal cases were reported. Most of the fatal cases were observed in men in the late stage of prostate cancer. Usually hepatotoxicity manifests itself several months after the start of treatment.

    During the treatment, regular monitoring of liver function is necessary. Functional liver tests should be performed before the start of treatment, regularly during treatment, as well as when there are signs suggesting a hepatotoxic effect of the drug. If there are signs of hepatotoxicity, the drug should be withdrawn. In patients with metastases of prostate cancer to the liver and in the presence of signs of impaired liver function, in cases where the expected benefit of the therapy exceeds the possible risk, the question of the continuation of the drug is decided individually.

    In very rare cases, with the use of Androkur®, there was a development of liver tumors that could lead to life-threatening intraabdominal bleeding. In the case of severe pain in the abdominal region, an increase in the liver, or signs of intra-abdominal hemorrhage, a differential diagnosis should take into account the possibility of liver tumors.

    The development of meningiomas (single and multiple) has been reported in connection with the long-term (for several years) administration of Androkur® in a dose of 25 mg or more.In the case of detection of meningioma in a patient receiving treatment with Androkur®, the drug should be discontinued.

    There have been reports of thromboembolic complications in patients taking Androcur®, although there was no causal relationship. In patients with previous thrombotic / thromboembolic diseases of the arteries or veins (for example, deep vein thrombosis, pulmonary embolism, myocardial infarction), with a history of cerebral circulation or in advanced stages of malignant diseases, the risk of thromboembolic complications is increased.

    During treatment with Androkur®, the development of anemia was reported. Therefore, during treatment with Androkur®, regular examination of peripheral blood should be performed.

    Patients with diabetes need to be closely monitored, as the need for oral hypoglycemic agents or insulin may change.

    The use of Androcur® in high doses can sometimes be accompanied by shortness of breath. In such cases, when making a differential diagnosis, one should take into account the known stimulatingthe effect of progesterone and synthetic gestagens on respiration, accompanied by hypocapnia and compensatory respiratory alkalosis. A special treatment with this symptom complex is not required.

    During treatment with Androkur®, the function of the cortical layer of the adrenal glands should be checked regularly, since, based on preclinical data, it is suggested that adrenal gland function may be suppressed in connection with the corticoid-like effect of Androkur® in high doses.

    The drug Androkur® contains 193.0 mg of lactose in 1 tablet. Patients with rare hereditary diseases of milk sugar intolerance, lactase deficiency, glucose malabsorption syndrome and galactose should apply this medication with caution.

    Effect on the ability to drive transp. cf. and fur:

    During the treatment with Androkur®, caution should be exercised when driving a car and engaging in other potentially hazardous activities requiring increased attention and speed of psychomotor reactions.

    Form release / dosage:

    Tablets of 100 mg.

    Packaging:

    For 10 tablets in a blister of PVC and aluminum foil. 6 blisters together with instructions for use are placed in a cardboard box.

    Storage conditions:

    Store at a temperature not higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    5 years.

    Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:П N015349 / 01
    Date of registration:07.10.2008 / 14.11.2016
    Expiration Date:Unlimited
    The owner of the registration certificate:Bayer Pharma AGBayer Pharma AG Germany
    Manufacturer: & nbsp
    Representation: & nbspBAYER, AOBAYER, AO
    Information update date: & nbsp05.09.2017
    Illustrated instructions
      Instructions
      Up